Information
-
Patent Application
-
20230295666
-
Publication Number
20230295666
-
Date Filed
April 21, 20213 years ago
-
Date Published
September 21, 2023a year ago
-
Inventors
-
Original Assignees
-
CPC
-
-
International Classifications
- C12N15/90
- C12N15/11
- C12N9/22
- C12N5/071
- C07K16/00
Abstract
Abstract: The present invention belongs to the field of biotechnology, and specifically relates to recombinant gene expression. The invention concerns a method of recombinant gene expression from a Chinese Hamster Ovary (CHO) cell, by using super-enhancer sequences for increased gene expression. Thus, the invention provides a method for producing an engineered CHO cell by introducing into the cell an exogenous nucleic acid molecule into or within 500 kb upstream or downstream of a super-enhancer as expression-enhancing sequence. The invention further provides an engineered CHO cell produced by the method. The invention further provides a method of producing a recombinant polypeptide. The invention is further directed to the use of a super-enhancer for transgene expression.
Claims
- 1. A method of producing an engineered Chinese Hamster Ovary (CHO) cell, the method comprising:
introducing into a CHO cell a construct for integration of an exogenous nucleic acid molecule into or within 500 kb upstream or downstream of an expression-enhancing sequence in the genome of the cell, the expression-enhancing sequence being at least 90% identical to a sequence selected from any one of SEQ ID NOs: 1-47.
- 2. The method according to claim 1, wherein the expression-enhancing sequence is selected from any one of SEQ ID NOs: 1-47.
- 3. The method according to claim 1, wherein integration of the exogenous nucleic acid molecule is within 100 kb upstream or downstream of the expression-enhancing sequence.
- 4. The method according to claim 1, wherein integration of the exogenous nucleic acid molecule is achieved by the CRISPR (Clustered Regulatory Interspaced Short Palindromic Repeats)/Cas9 method, TALEN (Transcription Activator-Like Effector Nuclease)-based method or ZFN (zinc-finger nuclease)-based method.
- 5. The method according to claim 4, wherein integration of the exogenous nucleic acid molecule is achieved by the CRISPR /Cas9 method.
- 6. The method according to claim 1, wherein the exogenous nucleic acid molecule integrates at two or more integration sites in the genome of the cell.
- 7. The method according to claim 1, wherein the exogenous nucleic acid encodes a polypeptide.
- 8. An engineered cell produced by the method according to claim 1.
- 9. A method of producing a recombinant polypeptide, the method comprising:
(i) introducing into a CHO cell a construct for integration of an exogenous nucleic acid molecule into or within 500 kb upstream or downstream of an expression-enhancing sequence in the genome of the cell, the expression-enhancing sequence being at least 90% identical to a sequence selected from any one of SEQ ID NOs: 1-47, to produce an engineered cell,(ii) culturing the engineered cell to recombinantly express the exogenous nucleic acid to produce a recombinant polypeptide encoded by the exogenous nucleic acid, and(iii) isolating the recombinant polypeptide.
- 10. Use of a nucleic acid sequence being at least 90% identical to a sequence selected from any one of SEQ ID NOs: 1-47 for transgene expression.
Priority Claims (1)
Number |
Date |
Country |
Kind |
20170926.8 |
Apr 2020 |
EP |
regional |
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/EP2021/060439 |
4/21/2021 |
WO |
|